Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 28'th May 2026
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
07:00am, Thursday, 28'th May 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
06:10pm, Monday, 11'th May 2026
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.06 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
04:01pm, Monday, 11'th May 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
10:06am, Thursday, 07'th May 2026
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average – Should You Sell?
03:11am, Friday, 03'rd Apr 2026
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $12.73 and traded as low as
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
07:00am, Tuesday, 03'rd Mar 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
01:02pm, Thursday, 12'th Feb 2026
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
06:06pm, Monday, 09'th Feb 2026
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $1.05 per share a year ago.
